Genopets

GENE (Genopets) demonstrates widespread structural and market decay across all evaluated dimensions. Active development has largely stalled, with official roadmaps frozen since 2023 and an absence of recent releases or commits. The tokenomics model features heavy insider concentration (57.5% allocated to private sales and team/advisors) alongside disparate circulating supply figures across tracking platforms. Market performance reflects terminal liquidity decay, with daily volume frequently falling to negligible levels. On the security side, there is no verified full third-party code audit, and automated contract scans reveal critical centralization risks on the BSC contract (including privileged mintability and the ability to modify token balances). Community Support had insufficient data (-1.0) and was excluded from the weighted score calculation. No qualifying red-flag events or confirmed fraud were identified, but the severe combination of stagnant development, high contract-level trust assumptions, and illiquidity warrants extreme caution.